The Food and Drug Administration (FDA) is rolling back warnings and restrictions on the diabetes drug rosiglitazone …
Avandia
The Vote Is In: FDA Panel Says Modify the Avandia Restrictions
After two attempted votes followed by computer glitches and giggles, the FDA panel to assess restrictions on the diabetes drug Avandia narrowly voted Thursday to modify the restrictions.
Breaking Down GlaxoSmithKline’s Billion-Dollar Wrongdoing
What the drug company did to promote Paxil, Wellbutrin and Avandia illegally — and what it meant for patients
Type 2 Diabetes Is Tougher to Treat in Kids and Teens
Type 2 diabetes, the kind linked with obesity, progresses much faster and is harder to treat in children than in adults, according to the disappointing results of a new study that sought to determine the best treatment for the …
“”
A Drug To Treat Diabetes Before It Begins
A new study shows that people who are high risk of developing Type 2 diabetes may be able to prevent the disease by taking pioglitazone (sold as Actos), a common drug for diabetes treatment. But experts say that doesn’t mean …
What the FDA’s Restriction of Avandia Means for Diabetes Patients
Now that the Food and Drug Administration has decided to strictly limit the use of the diabetes drug Avandia, what does that mean for patients?
FDA Severely Limits Use of Diabetes Drug Avandia
U.S. and European drug agencies came to a similar decision to severely restrict use of the antidiabetes medication rosiglitazone, or Avandia. But while the European Medicines Agency is suspending sales of the drug in E.U. …
FDA panel in favor of keeping Avandia on the market
Despite concerns that the popular GlaxoSmithKline diabetes drug Avandia could raise the risk for heart attack, a Food and Drug Administration (FDA) advisory panel voted today in favor of keeping the medication on the market. As the Wall Street Journal reports, 20 members of the 33-person panel voted in favor of keeping Avandia on the
…
FDA: Diabetes drug Avandia raises heart attack risk
A document released today by the U.S. Food and Drug Administration (FDA) concludes that, as critics have claimed since 2006, the hugely popular diabetes drug Avandia (rosiglitizone) increases the risk for heart attack. The 765-page briefing document released today in anticipation of an advisory panel meeting on July 13-14 to determine
…